Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Suramin . hexasodium salt

Purinergic receptor inhibitor
 
ALX-430-022-M050 50 mg 41.00 USD
 
ALX-430-022-M250 250 mg 158.00 USD
 
ALX-430-022-G001 1 g 372.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: BML-G430

Polysulfonated naphthylurea. P2x and P2y purinergic receptor antagonist. Antitumor, antiangiogenic and antiparasitic compound. Inhibits sirtuin 1, sirtuin 5 and topoisomerase II. Inhibits the cell surface binding of various growth factors including PDGF, EGF, FGFa and FGFb. Blocks association of G protein α and β/γ-subunits. Potent competitive inhibitor of reverse transcriptase and protects T lymphocytes against in vitro human immunodeficiency virus infection. Potent inhibitor of melanoma heparanase and tumor cell metastasis. Selective Edg-3 antagonist.

Product Specification

Formula:C51H34N6O23S6 . 6Na
 
MW:1429.1
 
Source:Synthetic.
 
CAS:129-46-4
 
MI:14: 9006
 
RTECS:QM7000000
 
Purity:≥98% (HPLC)
 
Appearance:White to off-white solid.
 
Solubility:Soluble in water or physiological saline; sparingly soluble in 95% ethanol; insoluble in benzene, ether or chloroform.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
430-022
Please mouse over
430-022

Product Literature References

Identification and characterization of novel sirtuin inhibitor scaffolds: B.D. Sanders, et al.; Bioorg. Med. Chem. 17, 7031 (2009), Abstract;
DBC1 is a negative regulator of SIRT1: J.E. Kim, et al.; Nature 451, 583 (2008), Abstract;
The Sirtuin family: therapeutic targets to treat diseases of aging: J.C. Milne & J.M. Denu; Curr. Opin. Chem. Biol. 12, 11 (2008), Abstract;
Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin: A. Schuetz, et al.; Structure 15, 377 (2007), Abstract;
Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins): J. Trapp, et al.; ChemMedChem 2, 1419 (2007), Abstract;
Pharmacological profiles of cloned mammalian P2Y-receptor subtypes: I. von Kügelgen; Pharmacol. Ther. 110, 415 (2006), Abstract;
Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38: P. Aksoy, et al.; BBRC 349, 353 (2006), Abstract;
Understanding the mechanism of the antimitogenic activity of suramin: K.M. Kathir, et al.; Biochemistry 45, 899 (2006), Abstract;
Suramin disrupts receptor-G protein coupling by blocking association of G protein alpha and betagamma subunits: W.C. Chung & J.C. Kermode; J. Phamacol. Exp. Ther. 313, 191 (2005), Abstract; Full Text
Suramin inhibits death receptor-induced apoptosis in vitro and fulminant apoptotic liver damage in mice: S.T. Eichhorst, et al.; Nat. Med. 10, 602 (2004), Abstract;
Catalytic topoisomerase II inhibitors in cancer therapy: A.K. Larsen, et al.; Pharmacol. Ther. 99, 167 (2003), Abstract;
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan: K.T. Howitz, et al.; Nature 425, 191 (2003), Abstract;
Suramin's development: what did we learn?: M. Kaur, et al.; Invest. New Drugs 20, 209 (2002), Abstract;
Fibroblast growth factors and their inhibitors: F. Manetti, et al.; Curr. Pharm. Des. 6, 1897 (2000), Abstract;
Conformational requirements of suramin to target angiogenic growth factors: P.A. Raj, et al.; Angiogenesis 2, 183 (1998), Abstract;
PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors: S.J. Charlton, et al.; Br. J. Pharmacol. 118, 704 (1996), Abstract;
Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells: R. Kopp & A. Pfeiffer; Cancer Res. 50, 6490 (1990), Abstract;
Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses: E. De Clerq; Cancer Lett. 8, 9 (1979), Abstract;

General Literature References

Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5: N. Ancellin & T. Hla; J. Biol. Chem. 274, 18997 (1999), Abstract;
Suramin. A potent inhibitor of melanoma heparanase and invasion: M. Nakajima, et al.; J. Biol. Chem. 266, 9661 (1991), Abstract;
Identification of allosteric antagonists of receptor-guanine nucleotide-binding protein interactions: R.R. Huang, et al.; Mol. Pharmacol. 37, 304 (1990), Abstract;
Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds: K.D. Jentsch, et al.; J. Gen. Virol. 68, 2183 (1987), Abstract;
Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells: R.J. Coffey, et al.; J. Cell Physiol. 132, 143 (1987), Abstract;
Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin: C. Betsholtz, et al.; Proc. Natl. Acad. Sci. USA 83, 6440 (1986), Abstract;
Suramin binds to platelet-derived growth factor and inhibits its biological activity: M. Hosang; J. Cell. Biochem. 29, 265 (1985), Abstract;
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III: H. Mitsuya, et al.; Science 226, 172 (1984), Full Text

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

Brochures
Stem Cells
Stem Cells
Download as PDF

Brochures
Epigenetics
Epigenetics
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,